Rosiglitazone, but not epigallocatechin-3-gallate, attenuates the decrease in PGC-1α protein levels in...

Area of Science:

• Biochemistry
• Metabolic Diseases
• Molecular Biology

Background:

• Insulin resistance is linked to altered lipid metabolism.
• PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is crucial for mitochondrial function and insulin sensitivity.
• Epigallocatechin-3-gallate (EGCG) is an anti-obesity agent that enhances lipid catabolism.

Purpose of the Study:

• To investigate the effects of EGCG and rosiglitazone (RGZ) on PGC-1α protein expression in insulin-resistant C2C12 myotubes.
• To compare the molecular mechanisms of EGCG and RGZ in improving insulin sensitivity.

Main Methods:

• C2C12 myoblasts were differentiated into myotubes.
• Insulin resistance was induced using palmitate treatment.
• PGC-1α protein expression and glucose uptake were measured before and after treatment with RGZ and EGCG.

Main Results:

• Palmitate treatment significantly reduced PGC-1α protein expression.
• RGZ restored PGC-1α expression in palmitate-treated cells, while EGCG did not.
• Both RGZ and EGCG significantly improved glucose uptake in palmitate-treated myotubes.

Conclusions:

• RGZ and EGCG both enhance insulin sensitivity and glucose uptake through distinct molecular pathways.
• RGZ's anti-diabetic effect involves, in part, the upregulation of PGC-1α protein expression.
• EGCG improves glucose uptake independently of PGC-1α modulation in this model.